Specificity and accuracy data for ligand-binding assays for macromolecules should be interpreted with caution

AAPS Journal

Volumn 10, Issue 3, 2008, Pages 433-434

  Findlay, John W A ^a  

^a GILEAD SCIENCES INC   (United States)

Author keywords

Catabolism; Cross reactivity; Metabolism; Pharmacokinetics; Protein; Validation

Indexed keywords

HUMAN GROWTH HORMONE; RECOMBINANT PROTEIN;

ACCURACY; CALIBRATION; DRUG INDUSTRY; DRUG METABOLISM; DRUG TOLERABILITY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; LIGAND BINDING; LIQUID CHROMATOGRAPHY; MACROMOLECULE; MASS SPECTROMETRY; PHARMACODYNAMICS; SENSITIVITY ANALYSIS; VALIDATION PROCESS;

IMMUNOASSAY; LIGANDS; MACROMOLECULAR SUBSTANCES; PROTEIN BINDING; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 57149111489     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-008-9047-2     Document Type: Editorial

References (14)

1. PhRMA report. Medicines in Development, Biotechnology, 2006. Available at http://www.phrma.org/files/biotech%202006.pdf. Accessed April 24, 2008.
2. V. P. Shah, K. K. Midha, S. Dighe, et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetics studies. Pharm. Res. 9:588-592 (1992).
3. V. P. Shah, K. K. Midha, J. W. A. Findlay, et al. Bioanalytical method validation - a revisit with a decade of progress. Pharm. Res. 17:1551-1557 (2000).
4. C. T. Viswanathan, S. Bansal, B. Booth, et al. Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand-binding assays. AAPS J. 9:E30-E42 (2007).
5. J. W. A. Findlay, W. C. Smith, J. W. Lee, et al. Validation of immunoassays for bioanalysis: A pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 21:1249-1273 (2000).
6. K. J. Miller, R. R. Bowsher, A. Celniker, et al. Workshop on bioanalytical methods validation for macromolecules: Summary report. Pharm. Res. 18:1373-1383 (2001).
7. B. DeSilva, W. Smith, R. Weiner, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20:1885-1900 (2003).
8. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation, US Department of Heath and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD, 2001.
9. J. W. Lee, R. S. Weiner, J. M. Sailstad, et al. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development. A conference report. Pharm. Res. 22: 499-511 (2005).
10. J. W. Lee, V. Devanarayan, Y. C. Barrett, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23:312-328 (2006).
11. B. Boulanger. Results of pilot dataset - and how this led to the design of a larger data set. In Variability of Ligand Binding Assays Used for PK Protein Drug Bioanalysis - Database Collected as a Follow-up to the 2006 AAPS Crystal City III Workshop, AAPS Annual Meeting, San Diego, CA, November, 2007.
12. H. Blasco, G. Lalmanach, E. Godat, et al. Evaluation of a peptide ELISA for the detection of rituximab in serum. J. Immunol. Methods. 325:127-139 (2007).
13. R. J. Wills, and B. L. Ferraiolo. The role of pharmacokinetics in the development of biotechnologically derived agents. Clin. Pharmacokinet. 23:406-414 (1992).
14. M. Rocci, V. Devanarayan, D. B. Haughey, and P. Jardieu. Confirmatory reanalysis of incurred bioanalytical samples. AAPS J. 9:E336-E343 (2007).